Literature DB >> 28042066

Repurposing Medications for Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A Manifesto for Change.

David C Currow1, Amy P Abernethy2, Marie Fallon3, Russell K Portenoy4.   

Abstract

The World Health Organization essential medications list for hospice/palliative care reflects that, with the judicious use of currently available medications, the majority of symptoms can be lessened, and some controlled completely. Even with optimal use of current medications, symptom control is still unacceptable for many people. Currently available medications offer great benefit to a minority of patients, some benefit to an additional group, and no benefit or harms to others. In symptom control, development of new drugs is advancing at a glacial pace, contrasting to the rapid advances seen in many other disciplines. Specialists in palliative care should agree on several principles consequently: 1) Access to symptom-control drugs codified in the World Health Organization Essential Medicines list deserves the strongest support from national policies and professional guidelines, especially in resource-challenged countries. 2) The optimal use of currently available symptom-control drugs cannot yield acceptably high rates of net benefits. 3) There is a compelling need to identify patient subgroups that are likely to benefit from available medications and provide rigorous empirical support for indications, dosing, and route of administration for clinical practice. 4) New therapies are needed requiring an accelerated effort to investigate further the pathophysiology, neurobiology, and pharmacogenetics of distressing symptoms, and factors contributing to variations in drug response. This development requires a lengthy lead time. 5) Smarter ways to promote new knowledge into practice are needed as no drug will be suitable for all patients. We need to improve clinical characterization and biomarker technology to bring the best drugs to the right patients every time.
Copyright © 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Symptom control; hospice/palliative care; investigational agents; pharmacogenetics; pharmacological treatment

Mesh:

Year:  2016        PMID: 28042066     DOI: 10.1016/j.jpainsymman.2016.10.358

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  2 in total

Review 1.  Medicinal cannabinoids in palliative care.

Authors:  Meera Agar
Journal:  Br J Clin Pharmacol       Date:  2018-08-12       Impact factor: 4.335

Review 2.  Implementation and Effectiveness of Integrating Palliative Care Into Ambulatory Care of Noncancer Serious Chronic Illness: Mixed Methods Review and Meta-Analysis.

Authors:  Linda C Chyr; Lyndsay DeGroot; Julie M Waldfogel; Susan M Hannum; Danetta H Sloan; Valerie T Cotter; Allen Zhang; JaAlah-Ai Heughan; Renee F Wilson; Karen A Robinson; Sydney M Dy
Journal:  Ann Fam Med       Date:  2022 Jan-Feb       Impact factor: 5.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.